Chief Cancer Prevention and Control Officer
Medical Director, CaTS Clinical Research Unit
Dr. Lance is professor of medicine, molecular and cellular biology and public health at the University of Arizona College of Medicine. He also serves as co-director of Cancer Prevention and Control and is the director of the Arizona Clinical and Translational Research and Education Consortium, Tucson Program at The University of Arizona Cancer Center.
Dr. Lance specializes in the treatment and prevention of gastrointestinal cancers. He serves as the principal investigator for several National Cancer Institute sponsored clinical trials.
Dr. Lance is a physician scientist with research interests that extend from basic investigations of colorectal carcinogenesis to clinical and translational studies that include oversight, as Principal Investigator (PI), of large phase III colorectal cancer prevention studies. He is Board Certified in Internal Medicine and Gastroenterology and has been consistently funded as a PI by NIH/NCI, and earlier the Veterans Administration, since the early 1990s. With this background and experience, Dr. Lance is well suited to be both overall PI of the University of Arizona Gastrointestinal Special Program of Research Excellence and Clinical Co-Leader of Project 1, “Molecular and Metagenomic Characteristics of Early-Onset Colorectal Cancers.” He has extensive experience of leading large multi-disciplinary research projects across multiple institutions.
Formerly, at Roswell Park Cancer Institute Dr. Lance was contracted as a site PI for NCI’s Polyp Prevention Trial, led by Arthur Schatzkin, PhD. Subsequently, at the University of Arizona Cancer Center, he has been PI of multi-institutional Program Project (P01) and R01 grants that have funded two placebo-controlled Phase III colorectal adenoma chemoprevention trials: ursodeoxycholic acid (UDCA) (n=1,285 participants); and, most recently, a selenium supplement + celecoxib, alone or in combination (n=1,824 participants). An invaluable, meticulously archived biobank, now comprising ~250,000 biospecimens (tissues, plasma, genomic DNA, urine, feces, etc.), collected from participants in these trials (and an earlier trial of Wheat Bran Fiber) has been the platform for over 40 publications in the last 5 years; preliminary fecal microbiota and bile acid data for Project 1 in the current application were derived from UDCA trial participant fecal specimens.
Dr. Lance is a tenured Professor of Medicine, Molecular and Cellular Biology, and Public Health. He is currently Deputy Director of the University of Arizona Cancer Center, Phoenix.
Dr. Lance obtained his undergraduate and medical degrees from the University of Cambridge in England. He completed residency and fellowship training in internal medicine and gastroenterology in England at the Universities of Birmingham and London. He came to the United States in 1981 as a postdoctoral fellow at the University of California, San Francisco.